| Naslov: | BAP1-defficient breast cancer in a patient with BAP1 cancer syndrome |
|---|
| Avtorji: | ID Blatnik, Ana (Avtor)
ID Ribnikar, Domen (Avtor)
ID Šetrajčič Dragoš, Vita (Avtor)
ID Novaković, Srdjan (Avtor)
ID Stegel, Vida (Avtor)
ID Grčar-Kuzmanov, Biljana (Avtor)
ID Boc, Nina (Avtor)
ID Perić, Barbara (Avtor)
ID Škerl, Petra (Avtor)
ID Klančar, Gašper (Avtor)
ID Krajc, Mateja (Avtor) |
|---|
| Datoteke: |  PDF - Predstavitvena datoteka, prenos (1,12 MB)
MD5: E522C712A5F7E5EC886C5E2CD9634B5E
|
|---|
| Jezik: | Angleški jezik |
|---|
| Tipologija: | 1.01 - Izvirni znanstveni članek |
|---|
| Organizacija: |  OI - Onkološki inštitut Ljubljana
|
|---|
| Povzetek: | BAP1 cancer syndrome is a rare and highly penetrant hereditary cancer predisposition. Uveal melanoma, mesothelioma, renal cell carcinoma (RCC) and cutaneous melanoma are considered BAP1 cancer syndrome core cancers, whereas association with breast cancer has previously been suggested but not confirmed so far. In view of BAP1 immunomodulatory functions, BAP1 alterations could prove useful as possible biomarkers of response to immunotherapy in patients with BAP1-associated cancers. We present a case of a patient with BAP1 cancer syndrome who developed a metastatic breast cancer with loss of BAP1 demonstrated on immunohistochemistry. She carried a germline BAP1 likely pathogenic variant (c.898_899delAG p.(Arg300Glyfs*6)). In addition, tumor tissue sequencing identified a concurrent somatic variant in BAP1 (partial deletion of exon 12) and a low tumor mutational burden. As her triple negative tumor was shown to be PD-L1 positive, the patient was treated with combination of atezolizumab and nab-paclitaxel. She had a complete and sustained response to immunotherapy even after discontinuation of nab-paclitaxel. This case strengthens the evidence for including breast cancer in the BAP1 cancer syndrome tumor spectrum with implications for future cancer prevention programs. It also indicates immune checkpoint inhibitors might prove to be an effective treatment for BAP1-deficient breast cancer. |
|---|
| Ključne besede: | BAP1, breast cancer, hereditary cancer syndromes, immunotherapy |
|---|
| Status publikacije: | Objavljeno |
|---|
| Verzija publikacije: | Objavljena publikacija |
|---|
| Datum objave: | 05.04.2022 |
|---|
| Založnik: | Springer |
|---|
| Leto izida: | 2022 |
|---|
| Št. strani: | str. 921–927 |
|---|
| Številčenje: | Vol. 29 |
|---|
| PID: | 20.500.12556/DiRROS-15559  |
|---|
| UDK: | 618.1 |
|---|
| ISSN pri članku: | 1340-6868 |
|---|
| DOI: | 10.1007/s12282-022-01354-0 |
|---|
| COBISS.SI-ID: | 104001539 |
|---|
| Avtorske pravice: | by Authors |
|---|
| Datum objave v DiRROS: | 19.09.2022 |
|---|
| Število ogledov: | 448 |
|---|
| Število prenosov: | 180 |
|---|
| Metapodatki: |     |
|---|
|
:
|
Kopiraj citat |
|---|
| | | | Objavi na: |  |
|---|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |
